

6-2016

Generation of Organ-conditioned Media and Applications for Studying Organ-specific Influences on Breast Cancer Metastatic Behavior

Matthew M. Piaseczny
Western University

Graciella M. Pio
Western University

Jenny E. Chu
Western University

Ying Xia
Western University

Kim Nguyen
Western University

See next page for additional authors

Follow this and additional works at: <https://ir.lib.uwo.ca/anatomypub>



Part of the [Anatomy Commons](#), and the [Cell and Developmental Biology Commons](#)

Citation of this paper:

Piaseczny, Matthew M.; Pio, Graciella M.; Chu, Jenny E.; Xia, Ying; Nguyen, Kim; Goodale, David; and Allan, Alison, "Generation of Organ-conditioned Media and Applications for Studying Organ-specific Influences on Breast Cancer Metastatic Behavior" (2016). *Anatomy and Cell Biology Publications*. 44.
<https://ir.lib.uwo.ca/anatomypub/44>

Authors

Matthew M. Piaseczny, Graciella M. Pio, Jenny E. Chu, Ying Xia, Kim Nguyen, David Goodale, and Alison Allan

Video Article

Generation of Organ-conditioned Media and Applications for Studying Organ-specific Influences on Breast Cancer Metastatic Behavior

Matthew M. Piaseczny^{*1,2}, Graciella M. Pio^{*1,2}, Jenny E. Chu^{1,2}, Ying Xia¹, Kim Nguyen^{1,3}, David Goodale¹, Alison Allan^{1,2,4,5}¹London Regional Cancer Program, London Health Sciences Centre²Department of Anatomy & Cell Biology, Schulich School of Medicine & Dentistry, Western University³Department of Biochemistry, Schulich School of Medicine & Dentistry, Western University⁴Department of Oncology, Schulich School of Medicine & Dentistry, Western University⁵Lawson Health Research Institute

*These authors contributed equally

Correspondence to: Alison Allan at alison.allan@lhsc.on.caURL: <https://www.jove.com/video/54037>DOI: [doi:10.3791/54037](https://doi.org/10.3791/54037)

Keywords: Medicine, Issue 112, Metastasis, breast cancer, organ tropism, ex vivo model system, organ-conditioned media, soluble factors, lymph node, bone, lung, brain

Date Published: 6/13/2016

Citation: Piaseczny, M.M., Pio, G.M., Chu, J.E., Xia, Y., Nguyen, K., Goodale, D., Allan, A. Generation of Organ-conditioned Media and Applications for Studying Organ-specific Influences on Breast Cancer Metastatic Behavior. *J. Vis. Exp.* (112), e54037, doi:10.3791/54037 (2016).

Abstract

Breast cancer preferentially metastasizes to the lymph node, bone, lung, brain and liver in breast cancer patients. Previous research efforts have focused on identifying factors inherent to breast cancer cells that are responsible for this observed metastatic pattern (termed organ tropism), however much less is known about factors present within specific organs that contribute to this process. This is in part because of a lack of *in vitro* model systems that accurately recapitulate the organ microenvironment. To address this, an *ex vivo* model system has been established that allows for the study of soluble factors present within different organ microenvironments. This model consists of generating conditioned media from organs (lymph node, bone, lung, and brain) isolated from normal athymic nude mice. The model system has been validated by demonstrating that different breast cancer cell lines display cell-line specific and organ-specific malignant behavior in response to organ-conditioned media that corresponds to their *in vivo* metastatic potential. This model system can be used to identify and evaluate specific organ-derived soluble factors that may play a role in the metastatic behavior of breast and other types of cancer cells, including influences on growth, migration, stem-like behavior, and gene expression, as well as the identification of potential new therapeutic targets for cancer. This is the first *ex vivo* model system that can be used to study organ-specific metastatic behavior in detail and evaluate the role of specific organ-derived soluble factors in driving the process of cancer metastasis.

Video Link

The video component of this article can be found at <https://www.jove.com/video/54037/>

Introduction

Breast cancer is the most frequently diagnosed cancer in women and the second leading cause of cancer-related deaths¹. Breast cancer's high mortality rate is mainly due to the failure of conventional therapy to mitigate and eliminate metastatic disease; approximately 90% of cancer-related deaths are due to metastasis². Understanding the underlying molecular mechanisms of the metastatic cascade is paramount to the development of therapeutics effective in both early and late-stage breast cancer.

Past research has helped elucidate the multistep nature of breast cancer metastasis and it is hypothesized that the outcome of both cancer progression and metastasis is largely dependent upon interactions between cancer cells and the host environment³. Clinical observations indicate that many cancers display organ tropism, *i.e.*, the tendency to preferentially metastasize to specific organs. In the case of breast cancer, a patient's disease typically spreads or metastasizes to 5 main sites, including the bone, lungs, lymph node, liver, and brain^{4,6}. Many theories have been developed to explain this process, but only a few have withstood the test of time. Ewing's theory of metastasis, proposed in the 1920s, hypothesized that the distribution of metastasis was strictly due to mechanical factors; whereby tumor cells are carried throughout the body by normal defined physiological blood flow patterns and simply arrest in the first capillary bed they encounter⁷. In contrast, Stephen Paget's 1889 "seed and soil" hypothesis suggested that additional molecular interactions were responsible for survival and growth of metastases, whereby cancer cells ("seeds") can only establish themselves and proliferate in organ microenvironments that produce appropriate molecular factors ("soil")⁸. Almost a century later, Leonard Weiss undertook a meta-analysis of previously published autopsy data and confirmed Ewing's prediction that many metastatic tumors detected at the time of autopsy were found in the anticipated proportions that would be expected if metastatic organ tropism was determined by blood flow patterns alone. However, in many instances there were fewer or more metastases formed at certain sites than would be expected by Ewing's proposed mechanical factors⁹. These accounts and theories suggest that specific organ

microenvironments play a critical role in the dissemination patterns and subsequent growth and survival of many cancers, including breast cancer.

Past research efforts have mainly focused on tumor-cell derived factors and their contribution to the organ tropism observed in breast cancer metastasis¹⁰⁻¹², however little research has explored factors derived from the organ microenvironment that may provide a favorable niche for the establishment of breast cancer metastases. This is largely attributable to the technical challenges of studying components of the organ microenvironment *in vitro*.

The current article describes a comprehensive *ex vivo* model system for studying the influence of soluble components of the lymph node, bone, lung, and brain on the metastatic behavior of human breast cancer cells. Previous studies have validated this model system by demonstrating that different breast cancer cell lines display cell-line specific and organ-specific malignant behavior in response to organ-conditioned media that corresponds to their *in vivo* metastatic potential¹³. This model system can be used to identify and evaluate specific organ-derived soluble factors that may play a role in the metastatic behavior of breast and other types of cancer cells, including influences on growth, migration, stem-like behavior, and gene expression, as well as the identification of potential new therapeutic targets for cancer. This is the first *ex vivo* model system that can be used to study organ-specific metastatic behavior in detail and to evaluate the role of organ-derived soluble factors in driving the process of cancer metastasis.

Protocol

All animal studies were conducted in accordance with the recommendations of the Canadian Council on Animal Care, under protocols approved by the Western University Animal Use Subcommittee.

1. Organ Isolation (Lung, Brain, Bone, Lymph Node)

1. Prepare four sterile 50 ml conical tubes (one for each organ to be isolated) containing approximately 30 ml of sterile phosphate-buffered saline (PBS). Pre-weigh each tube of PBS using an electronic balance.
2. Euthanize 6-12 week old mouse by CO₂ inhalation. Mice should be left in the CO₂ chamber for approximately 1 - 2 min or until the mouse stops moving and breathing. Successful euthanasia can be further confirmed by a lack of heartbeat when checked manually with a finger. Avoid cervical dislocation as this method may rupture blood vessels of the neck leading to difficulty removing axillary lymph nodes. Note: Previous work has specifically used healthy female nude mice, Hsd:ATHymic Nude-Foxn1^{nu}¹³.
3. In a sterile tissue culture hood, place the mouse on its back on a polystyrene foam pad, spread the limbs and use pins to keep them in place.
4. Using sterile forceps and scissors, cut the abdominal skin at the midline at the genitalia and cut upwards toward the mouth. Gently pull back the abdominal skin from the abdominal muscles and pin in place on the polystyrene foam pad.
5. Locate the axillary, brachial, and inguinal lymph nodes. Note: Lymph nodes are usually surrounded by fatty tissue. The inguinal lymph nodes are the easiest to locate as they are found superficially at the junction of two blood vessels on the pulled back abdominal skin. Axillary and brachial lymph nodes are located deeper within the tissue and require gentle maneuvering of tissue.
 1. After you have located the lymph nodes, use the scissors to gently and carefully cut the lymph nodes away from the skin, fat and vessels and remove them from the mouse. To confirm proper dissection, roll the forceps over the removed tissue. If a hard lump exists when rolling the forceps over the tissue, then a lymph node has likely been removed successfully.
 2. Place removed lymph nodes in ice cold PBS.
6. Using the forceps and scissors, open the abdominal cavity by cutting through the exposed abdominal wall in an upward motion towards the chest. Carefully cut through the sternum, exposing the thoracic cavity.
7. Locate the diaphragm below the lungs and cut the diaphragm. It should pull towards the ribs due to tension.
8. Lift the lungs from underneath and cut the underlying tissue towards the trachea. This allows the lungs to be removed freely from the thoracic cavity. Remove the heart and lungs *en bloc* and place in ice cold PBS. The heart can be removed from the lungs here or just before weighing in Step 2.
9. Remove the pins, keeping the mouse in place on the polystyrene foam pad. Turn the mouse over and cut the skin of the lower back all the way across from flank to flank.
10. Using a sterile piece of gauze to hold the torso of the mouse, peel the back skin of the mouse over the legs and feet of the mouse.
11. Using the same piece of sterile gauze, hold the lower leg in place, carefully break the ankle joint of the mouse foot and peel the skin over the joint proximally towards the knee joint.
12. Using scissors, remove the tibia free from the knee joint and place in ice cold PBS.
13. Repeat steps 1.11) to 1.12) with opposite limb.
14. Using forceps, hold the femur in place, cut away surrounding muscle tissue using the scissors and remove the femur, placing it in ice cold PBS.
15. Repeat step 1.14) with opposite limb.
16. Using a new piece of sterile gauze, hold the head of the mouse in place. Using forceps and scissors, gently remove the skin to expose the skull. Using scissors, carefully cut the occipital skull from the top center in a straight and downward line to expose the posterior brain.
17. Using forceps, scoop underneath the brain towards the anterior and remove the whole brain. Place the brain in ice cold PBS.
18. Repeat steps 1.1) to 1.17) for at least four mice.

2. Organ Weighing

1. Following organ isolation, weigh each PBS tube containing lung and brain tissue using an electronic balance.
2. Calculate the weight difference by subtracting the pre-isolation weight (PBS only) from the weight of the PBS tube + organs (lung and brain).
3. Determine the amount of media needed to resuspend tissue fragments from the calculated weight difference.

Note: Lung and brain tissue are weight normalized by resuspension in a 4:1 media:tissue ratio (vol/wt).

3. Generation of Lung- and Brain- Conditioned Media

1. In a sterile tissue culture hood, invert PBS tubes containing lung or brain three times to remove residual blood from organs and aspirate PBS containing blood. Repeat with fresh cold PBS until solution appears clear with no evidence of blood.
2. Place lungs and brains in separate 60 mm² glass petri dishes. Using two sterile scalpel blades, mince lungs or brains by repeatedly slicing back and forth until tissue fragments are approximately ~ 1 mm³ in size.
3. Resuspend tissue fragments in appropriate volume (determined previously in step 2.3) of Dulbecco's Modified Eagle's Medium (DMEM):F12 media supplemented with 1x concentrated mitogen supplement and penicillin (50 µg/ml)/streptomycin (50 µg/ml).
4. Add resuspended lung or brain tissue fragments to one well of a 6-well plate.
5. Incubate tissue fragments in media for 24 hr at 37 °C and 5% CO₂. Following incubation, collect conditioned media for each tissue and further dilute by adding three equivalent volumes of fresh media in a 50 ml conical tube.
6. Centrifuge at 1,000 x g in diluted conditioned media for each organ at 4 °C for 15 min to remove large tissue debris. Collect media supernatant and filter through a 0.22 µm syringe filter.
7. Pool conditioned media from each organ (*i.e.*, lung with lung and brain with brain) from multiple mice to account for mouse-to-mouse variability. Aliquot and store conditioned media at -80 °C until use.

4. Generation of Bone Marrow-conditioned Media

1. In a sterile tissue culture hood, trim excess tissue from the bone and remove epiphyses (end pieces) from the bones with scissors.
2. Using a 27 ½ G needle, flush medullary cavity of bones by pushing 1 ml of PBS through the center of each bone. This will allow you to collect bone marrow stromal cells (BMSC) into a fresh tube containing PBS.
3. Centrifuge at 1,000 x g for 5 min at 4 °C and wash BMSC twice with PBS. Resuspend bone marrow stromal cells in 20 ml of bone stromal cell growth media (DMEM:F12 media supplemented with 1x concentrated mitogen supplement, penicillin (50 µg/ml)/streptomycin (50 µg/ml) and 10% fetal bovine serum (FBS)).
4. Plate 10 ml of resuspended bone marrow stromal cells in one T75 flask.
Note: Combine and plate cells from every 2 mice in each T75 flask; for four mice, two T75 flasks are needed (approximately 1 x 10⁷ cells/flask).
5. Incubate bone marrow stromal cells in bone stromal cell growth media for 24 hr at 37 °C and 5% CO₂. Following incubation, remove media from both T75 flasks and put into new T75 flask, label this flask as "Floater Flask". Add fresh bone stromal cell growth media to previous 2 flasks and incubate all 3 flasks at 37 °C and 5% CO₂.
6. After cells reach approximately 70% confluency (approximately 5 - 7 days) passage cells. To do this, remove medium and wash cells twice with PBS (3 ml each wash). Remove PBS and add 3 ml of trypsin/EDTA solution, ensuring that trypsin covers the entire surface of the flask. After cells lift off the flask (~ 2 - 3 min), stop trypsinization reaction by adding 3 ml bone stromal cell growth media). Centrifuge 900 x g for 5 min at 4 °C, discard media, and resuspend cells in 10 ml of fresh bone stromal cell growth media.
7. Pool cells from all flasks and passage 1:5 into three new T75 flasks and incubate at 37 °C and 5% CO₂. After cells once again reach 70%, repeat step 4.6 and pool and passage all adherent cells a second time. Re-plate all cells to four T75 flasks and incubate 37 °C and 5% CO₂. Bone stromal cell growth media should be used for all steps.
8. Allow cells to reach confluence, wash cells three times with PBS and add bone stromal cell collection media (DMEM:F12 media + 1x concentrated mitogen supplement + penicillin (50 µg/ml)/streptomycin (50 µg/ml); 10 ml/T75), making sure that this media is free of FBS. Collect bone marrow-conditioned media 72 hr later, filter through a 0.22 µm filter, pool, aliquot, and store at -80 °C until use.
9. If desired, confirm the phenotype of the isolated bone marrow stromal cells (BMSC) using antibodies against mouse Sca-1, CD105, CD29, and CD73, CD44, using standard flow cytometry techniques as described previously¹³.

5. Generation of Lymph Node-conditioned Media

1. In a sterile tissue culture hood, invert PBS tube containing lymph nodes three times to remove residual blood from lymph nodes and aspirate bloody PBS. Repeat with fresh cold PBS until solution appears clear with no evidence of blood.
2. Place lymph nodes in 60 mm² glass petri dishes. Using two sterile scalpel blades, mince lymph nodes by repeatedly slicing back and forth until tissue fragments are approximately 1 mm³ in size.
3. In a conical tube, resuspend tissue fragments in 10 ml of Roswell Park Memorial Institute 1640 (RPMI1640) media supplemented with penicillin (50 µg/ml)/streptomycin (50 µg/ml), 5 x 10⁻⁵ M sterile β-mercaptoethanol (1.75 µl/500 ml media) and 10% FBS.
4. Centrifuge at 900 x g for 5 min at 4 °C and resuspend all cells in 30 ml media. Add 5 ml media/well in a 6-well plate and incubate for 7 days at 37 °C and 5% CO₂.
5. Following the 7 day incubation, discard media, wash adherent cells with 5 ml warm PBS and add 5 ml fresh media to each well. Allow cells to grow to confluency (approximately 5 - 7 days), trypsinize, pool all cells, and passage as described in step 4.6. Re-plate cells to 6-well plate. Repeat this step three times.
6. After three passages, allow cells to grow to confluency, wash wells three times with PBS and add 2 ml/well of DMEM:F12 + 1x concentrated mitogen supplement and penicillin (50 µg/ml)/streptomycin (50 µg/ml), ensuring that this media is free of FBS. Collect lymph node-conditioned media after 72 hr, pool, aliquot, and store at -80 °C until use.
7. If desired, confirm the phenotype of the isolated lymph node stromal cells (LNSC) using antibodies against mouse CD45 and gp38, using standard flow cytometry techniques as described previously¹³.

6. Use of Organ-conditioned Media for Downstream Assays Related to Metastatic Behavior of Cancer Cells

1. Once the organ-conditioned media has been generated as described in steps 1 - 5, use it to carry out different downstream cell and molecular biology assays in order to determine the influence of soluble organ-derived factors on the metastatic behavior of cancer cells. Examples of standard assays (described elsewhere in the literature) include protein arrays¹³, cellular growth assays¹³, cellular migration assays¹³, tumorsphere formation¹⁴, and RT-PCR¹⁵. The original base media used to generate the organ-conditioned media (*i.e.*, unconditioned DMEM:F12 media supplemented with 1x concentrated mitogen supplement and penicillin (50 µg/ml)/streptomycin (50 µg/ml) should be used as a negative control.

Representative Results

Generation of Organ-conditioned Media

An overview diagram/schematic of the process of organ isolation and generation of conditioned media is presented in **Figure 1**, with representative photographic images of the procedure shown in **Figure 2**. It should be noted that when this protocol was first under development, liver was included in our analysis because it is a common site of breast cancer metastasis. However, because of the large amount of proteases produced and secreted by the liver, it is very difficult to keep the liver viable long enough to generate good quality conditioned media. Liver-conditioned media is also not stable once isolated, and there tends to be a lot of protein precipitate, likely for the same reason. Therefore liver was not included in any further analysis.

For the generation of lymph node- and bone-conditioned media specifically, the phenotype of isolated stromal cells (LNSCs and BMSCs) can be confirmed by observing their cellular morphology by microscopy combined with immunophenotyping by standard flow cytometry. Stromal cells should be adhesive in culture, with LNSCs demonstrating an elongated and fibroblastic phenotype (**Figure 3A**) and BMSCs demonstrating a smaller appearance (**Figure 3C**). Flow cytometric analysis confirms that LNSCs are largely CD45⁻ and gp38⁺, with ~ 60% of cells possessing a CD45⁻gp38⁺ phenotype indicative of LNSCs¹⁶ (**Figure 3B**). The BMSCs should be positive for CD44 and CD29, weakly positive for CD105 and Sca-1, and negative for CD73 (**Figure 3D - H**), indicative of BMSCs^{17,18}.

Breast Cancer Cell Response to Organ-appropriate Migration Patterns and Gene Expression Changes

Using this *ex vivo* model system, it has previously been demonstrated that human breast cancer cells with varying genetic backgrounds exhibit differential migration and growth patterns towards specific organ conditions. Notably, these patterns reflect the known metastatic dissemination patterns of these cell lines *in vivo*¹³. In the current study, bone (231-BoM)- and lung (231-LM2)-seeking variants of the MDA-MB-231 human breast cancer cell variants (a kind gift from Dr. Joan Massagué^{11,12}) have also been used in a transwell migration assay to confirm organ-appropriate migration patterns. The results demonstrate that the bone-seeking 231-BoM variant preferentially migrates to the bone marrow-conditioned media over brain- and lung- conditioned media (**Figure 4A, left**). Similarly, the lung-seeking 231-LM2 variant preferentially migrates to lung-conditioned media over bone marrow-conditioned media and brain-conditioned media (**Figure 4A, right**). Furthermore, RT-qPCR analysis demonstrates that exposure of parental MDA-MB-231 breast cancer cells to bone- or lung-conditioned media causes an upregulation of genes associated with bone-specific metastasis (CXCR4, IL-11, TGFβ1) or lung-specific metastasis (VCAM1) of breast cancer cells *in vivo*^{11,12} (**Figure 4B**). These results demonstrate the validity of the *ex vivo* system with regards to the expected organ tropism of breast cancer cells *in vivo*, and indicates that soluble factors present in organ-conditioned media can influence metastatic cell phenotype in addition to promoting migration.

Organ-conditioned Media Contains Potential Soluble Mediators of Metastatic Behavior

A biotin label-based mouse antibody array was used to assess the presence and identity of common soluble factors in organ-conditioned media from different organs. This array includes antibodies against 308 of the most common soluble mouse proteins. This protein array has previously been used to identify soluble factors of interest associated with the metastatic cascade present within the lung and bone marrow conditioned media as shown in Chu *et al* (2014) and Pio *et al* (2015) respectively^{13,14}. In the current study, protein array results are shown for basal media (**Figure 5A**) compared to lymph node- (**Figure 5B**) and brain-conditioned media (**Figure 5C**). Highlighted beside each array are soluble factors present in the media that have been found to be associated with steps in the metastatic cascade in the literature¹⁹⁻²⁹. These soluble factors may be worth investigating as potential mediators of secondary metastases within these organ sites.




Figure 1. Overview Schematic of the Process of Organ Isolation and Generation of Conditioned Media. Tissues (lungs, brain, femur, tibia and lymph nodes) are harvested from the mouse. Lungs, brain and lymph nodes are minced with a scalpel. Bone marrow is harvested from the medullary cavity of the bones by pushing PBS through the cavity with a 27½ G needle. Lung and brain tissue fragments are incubated for a period of 24 hr before diluting with three equivalent volumes of fresh basal media and collected to make lung- and brain-conditioned media. Bone marrow and lymph node stromal cells are passaged 2 - 3 times before incubating with basal media to make bone and lymph node-conditioned media. Harvested media can be pooled and stored at -80 °C until ready for use in downstream assays such as protein arrays, cellular growth assays, cellular migration assays, tumorsphere formation, and RT-PCR. [Please click here to view a larger version of this figure.](#)




Figure 2. Representative Photographic Images of the Procedure for Organ Isolation and Generation of Conditioned Media. At Day 0, the lungs, brain, femur, tibia and lymph nodes are collected from the mouse. The lungs, brain and lymph nodes are placed in a 60 mm² glass petri dish and minced with two scalpel blades to approximately 1 mm³ in size. The bone marrow is harvested from the medullary cavity of the bones by pushing PBS through the cavity with a 27 ½ G needle into a fresh tube of PBS. The lung and brain tissue fragments are incubated for a period of 24 hr at 37 °C and 5% CO₂ before diluting with three equivalent volumes of fresh media and collected to make lung- and brain-conditioned media after 24 hr. The bone marrow and lymph node stromal cells are incubated at 37 °C and 5% CO₂ and passaged 2 - 3 times (~ 3 weeks total) before replacing media with serum-free basal media to make bone and lymph node-conditioned media. [Please click here to view a larger version of this figure.](#)




Figure 3. Characterization of Isolated Lymph Node and Bone Marrow Stromal Cells. (A) Bright-field microscopy image showing the morphology of lymph node stromal cells (LNSCs). (B) Representative flow cytometry analysis of LNSCs using a phycoerythrin (PE)-conjugated gp38 antibody and a fluorescein isothiocyanate (FITC)-conjugated CD45 antibody. (C) Bright field microscopy image showing the morphology of bone marrow stromal cells (BMSCs). (D-H) Representative flow cytometry analysis of BMSCs using PE conjugated (black profiles) antibodies against (D) CD44, (E) CD106, (F) Sca-1, (G) CD29, (H) CD73 antibodies relative to the isotype control (white profiles). A minimum of 10,000 viable events were collected per sample. This figure has been modified from ¹³. [Please click here to view a larger version of this figure.](#)




Figure 4. Organ-appropriate Migration Patterns and Gene Expression Changes in Response to Organ-conditioned Media. (A) Bone-seeking 231-BoM variants (*left, striped bars*) or lung-seeking 231-LM2 variants (*right, striped bars*) of the MDA-MB-231 human breast cancer cell line as well as parental MDA-MB-231 cells (*both panels, solid bars*) were plated onto gelatin-coated inserts (with 8 μ m pores) prior to placement in basal media (DMEM:F12+ concentrated mitogen supplement) or organ-CM. Plates were incubated at 37 °C and 5% CO₂ for 18 hr. (B) Whole population parental MDA-MB-231 cells were exposed to either bone-CM (*left*) or lung-CM (*right*) for 48h. RNA was isolated and quantified using RT-qPCR. Gene expression changes in response to organ-CM (*black bars*) were normalized to GAPDH and expressed relative to baseline expression in basal media (*grey bars*). Data are presented as mean \pm SEM (N = 3; fold-change from respective negative control of basal media). * = significantly different from basal media; δ = significantly different from parental cell line treated with the same media conditions; P <0.05, ANOVA. [Please click here to view a larger version of this figure.](#)




Figure 5. Organ-conditioned Media Contains Potential Soluble Mediators of Metastatic Behavior. A biotin label-based mouse antibody array was used to identify soluble factors present in lymph node-CM and brain-CM. Membranes were incubated with biotinylated samples of (A) basal media (DMEM:F12+ concentrated mitogen supplement), (B) lymph node-CM or (C) brain-CM at 4 °C O/N and visualized using chemiluminescence. Blue ovals indicate internal positive controls, lined boxes indicate internal negative controls and solid boxes indicate soluble factors of interest that are potentially involved in the metastatic behavior of breast cancer cells to the lymph node or brain. [Please click here to view a larger version of this figure.](#)

Discussion

Metastasis is a complex process by which a series of cellular events are ultimately responsible for tissue invasion and distant tumor establishment^{4,30,31}. The *ex vivo* model system presented here can be utilized to study two important aspects of metastatic progression: cancer cell homing or migration to a specific organ ("getting there") and growth in that organ ("growing there"). Many studies have previously focused on identifying key molecular characteristics associated with the cancer cells themselves that contribute to the metastasis process. For example, work done by Joan Massagué's group has identified distinct gene signatures associated with lung-specific, bone-specific, and brain-specific patterns of spread^{10-12,32}. While this work provides important insights with regards to the contribution of cancer cells to this process, much less is known about the role of organ-specific factors contributed by the secondary microenvironment, which has remained relatively challenging to study¹³.

This *ex vivo* model system has previously been validated as an accurate representation of the secondary organ microenvironment by demonstrating that breast cancer cell line-specific migration and growth in organ-CM mirrors these cell lines' *in vivo* pattern of metastatic spread. A study by Chu and colleagues used four different human breast cancer cell lines with varying metastatic potential *in vivo*, including MDA-MB-231 and SUM-159 (highly metastatic, metastasize to the lymph node, lung, liver, bone and brain *in vivo*) and the SUM-149 and MDA-MB-468 (moderately metastatic, metastasize to the lymph node and lung *in vivo*) in. Both the MDA-MB-231 and SUM-159 cell lines displayed enhanced migration toward bone marrow-, lymph node- and lung-CM while the SUM-149 and MDA-MB-468 cell lines preferentially migrated toward lung-CM¹³. The current study demonstrates that bone- and lung-seeking MDA-MB-231 variants both prefer to migrate to bone marrow- and lung-CM respectively and that exposure to organ-CM can promote the expression of bone- and lung-associated metastatic genes previously identified by Massagué and colleagues^{11,12}. Taken together, these results demonstrate that organ-CM provides an *ex vivo* platform representative of organ-specific soluble factors found *in vivo* that influence the phenotype and behavior of breast cancer cells.

Identification of soluble factors present within specific organs and their relative levels of expression provides a starting point for determining their potential influence on cancer cell behavior. Furthermore, using techniques such as immunodepletion can allow the user to effectively deplete a protein of interest from organ-CM to determine its effect on *in vitro* cellular behavior. For example, many soluble factors present within specific organ microenvironments function as chemoattractants and have the potential to induce cellular migration and proliferation. Previous work done using lung-CM has led to the identification of many soluble factors present in lung-CM that may act as chemoattractants for breast cancer cells, including osteopontin (OPN) and L-selectin (SELL)¹³. By immunodepleting these factors from lung-CM, Chu and colleagues were able to demonstrate reduced cellular migration and/or growth of highly metastatic MDA-MB-231 breast cancer cells¹³. These results show that conditioned media generated from whole organs provides a valuable resource for studying the effects of specific soluble factors on cancer cell behavior, through the use of traditional *in vitro* techniques.

Although this is a fairly straightforward model system, there are some steps in the experimental protocol that are critical for successful generation of organ-conditioned media. First, the use of mice between the defined ages of 6-12 weeks for harvesting of organs is important in order to control for age-related effects, either related to development (before 6 weeks) or related to aging in older mice. Secondly, sterility is of utmost importance throughout the protocol and can be best ensured through the use of rigorous aseptic technique and work in a sterile tissue culture hood, using sterilized tissue culture consumables and reagents as well as mild antibiotics in all culture media and supplements (*i.e.*, penicillin/streptomycin). One of the challenges with using *in vivo* or *ex vivo* model systems is the inherent animal-to-animal variability. If this observed, troubleshooting steps include pooling of conditioned media obtained from multiple batches of mice before use in downstream experiments, as well as ensuring that lung- and brain-conditioned medias are accurately weight-normalized in each media collection experiment by resuspension in a 4:1 media:tissue ratio (volume/weight). In addition, the primary lymph node and bone marrow stromal cells should not be allowed to exceed 70% confluency at any given passage or be grown beyond 5 total passages, otherwise they will terminally differentiate.

Modifications to the protocol presented in this article could be envisioned to allow application to different fields of research. Although this model has so far been used exclusively for breast cancer research, it can potentially be used to study the role of organ-derived soluble factors in other types of cancer as well as additional normal physiological and disease states. In addition, while this method has been used here with immunocompromised nude mouse models, this technique is theoretically not limited to this species of mice and even could potentially be used with other types of animal models.

While this model provides important insight as to the contribution of specific organ-derived soluble factors on cancer cell behavior, it is not without its limitations. First this model focuses solely on the soluble component of organ microenvironments, which neglects the importance of the extracellular matrix (ECM). The ECM is the non-cellular component present within all tissue types and functions to provide both a physical scaffold for cells, as well as the ability to induce crucial biochemical and biomechanical cues required for various cellular processes, including morphogenesis, cellular differentiation and homeostasis³³⁻³⁵. Importantly, the physical and biochemical composition of the ECM is widely heterogeneous and can vary greatly between tissues types. Therefore, the tissue-specific composition of the ECM may also have an influence on organ tropism during cancer metastasis that may be overlooked with this model. The ECM may also act to concentrate specific soluble factors in a way that appropriately presents them to certain cells, and without this fine tuning of the ECM, the induction of cellular signaling may be diminished or altered³⁶. Although the model mentioned in this paper lacks an appropriate ECM component, many studies could be strengthened by using a complimentary approach utilizing both the model mentioned here along with a suitable ECM component. For example, commercially available primary organ fibroblasts that synthesize endogenous ECM or recombinant ECM components could be used in addition to generated organ-CM to determine the full extent of the whole organ microenvironment on cellular behavior.

It is possible that the soluble microenvironment generated from organ-CM may not appropriately mimic what is present physiologically during the process of metastasis. Cancer cell survival, growth and progression are highly dependent upon cancer cell-host interactions^{4,30,31}. Generation of whole organ-CM may result in the presence of soluble factors not normally expressed by cell types that interact with cancer cells during metastatic progression. Furthermore, it has previously been demonstrated that the presence of a primary tumor can modulate the microenvironment of distant metastatic sites, thereby "priming" them for metastasis³⁷. Since the current protocol uses organs derived from healthy, non tumor-bearing mice, it would be worthwhile to compare the soluble factors derived from organs from mice bearing a primary breast tumor.

Due to the mechanical separation of whole organs during the generation of various organ-CM, intracellular factors may be released into the surrounding media which may not normally be encountered physiologically by cancer cells. Additionally, bone- and lymph node-derived conditioned media requires the culturing of stromal cells isolated from these organs prior to their collection. The cell types present during *ex vivo* culturing may not accurately represent the breadth of cellular types encountered physiologically by cancer cells. While stromal cells principally secrete many factors associated with various organ microenvironments, using these methods may not account for the influence of other cell types present within tissues and organs³⁸. Finally, we included a mitogen supplement in the base media used to generate organ-conditioned media, because we found that this was required to maintain the viability of both the cultured organs (lung and brain) and the isolated BMSC and LN5C. However, we recognize the caveat that the presence of this mitogen supplement could have stimulated the organs to artificially produce soluble factors that they might not normally make,

In summary, many studies have indicated that specific organ microenvironments can profoundly influence tumor cell biology. Despite the discussed limitations, the *ex vivo* model system presented here represents a comprehensive technique for studying the influence of the soluble microenvironment of many solid organs on cellular behavior. In the laboratory of the authors, this model system has been and continues to be used as a means of studying many of the cellular events associated with metastasis, including invasion, migration, proliferation, stem-like behavior, and gene expression changes. The data gained from these studies could in turn inform the potential clinical application of this model system to primary breast cancer cells isolated from patient tumors in order to determine their response to various microenvironments representing potential metastatic sites. Taken together, it is hoped that further understanding of the interaction between the microenvironment and tumor cells during the process of metastatic organ tropism will lead to improvement of cancer treatment in the future.

Disclosures

The authors declare that they have no competing financial interests.

Acknowledgements

This work was supported by grants from the Canadian Breast Cancer Foundation-Ontario Region, the Canada Foundation for Innovation (No. 13199), and donor support from John and Donna Bristol through the London Health Sciences Foundation (to A.L.A.). Studentship and fellowship support were provided by the Ontario Graduate Scholarship program (Province of Ontario, to G.M.P. and J.E.C.), the Canada Graduate Scholarship-Master's program (to M.M.P.), the Canadian Institutes of Health Research (CIHR)-Strategic Training Program (to M.M.P., G.M.P. and J.E.C.) and the Pamela Greenaway-Kohlmeier Translational Breast Cancer Research Unit at the London Regional Cancer Program (to M.M.P., G.M.P., J.E.C. and Y.X.). A.L.A. is supported by a CIHR New Investigator Award and an Early Researcher Award from the Ontario Ministry of Research and Innovation.

References

1. Canadian Cancer Statistics. www.cancer.ca *Canadian Cancer Society*. Toronto, ON, (2014).
2. Siegel, R. L., Miller, K. D., & Jemal, A. Cancer statistics, 2015. *CA Cancer J Clin.* **65** (1), 5-29 (2015).
3. Fidler, I. J. The organ microenvironment and cancer metastasis. *Differentiation.* **70** (9-10), 498-505 (2002).
4. Chambers, A. F., Groom, A. C., & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. *Nat Rev Cancer.* **2** (8), 563-572 (2002).
5. Kennecke, H. *et al.* Metastatic behavior of breast cancer subtypes. *J Clin Oncol.* **28** (20), 3271-3277 (2010).
6. Nguyen, D. X., Bos, P. D., & Massague, J. Metastasis: from dissemination to organ-specific colonization. *Nat Rev Cancer.* **9** (4), 274-284 (2009).
7. Ewing, J. Neoplastic Diseases: A Treatise on Tumors. *Am J Med Sci.* **176**(2), 278 (1928).
8. Paget, S. The distribution of secondary growths in cancer of the breast. 1889. *Cancer Metastasis Rev.* **8** (2), 98-101 (1989).
9. Weiss, L. Comments on hematogenous metastatic patterns in humans as revealed by autopsy. *Clin Exp Metastasis.* **10** (3), 191-199 (1992).
10. Bos, P. D. *et al.* Genes that mediate breast cancer metastasis to the brain. *Nature.* **459** (7249), 1005-1009 (2009).
11. Kang, Y. *et al.* A multigenic program mediating breast cancer metastasis to bone. *Cancer Cell.* **3** (6), 537-549 (2003).
12. Minn, A. J. *et al.* Genes that mediate breast cancer metastasis to lung. *Nature.* **436** (7050), 518-524 (2005).
13. Chu, J. E. *et al.* Lung-Derived Factors Mediate Breast Cancer Cell Migration through CD44 Receptor-Ligand Interactions in a Novel *Ex Vivo* System for Analysis of Organ-Specific Soluble Proteins. *Neoplasia.* **16** (2), 180-IN127 (2014).
14. Pio, G., Piaseczny, M., Allan, A. *The Role of Bone-Derived Osteopontin in the Migration and Stem-Like Behavior of Breast Cancer Cells.* AACR 2015, (2015).
15. Deepak, S. *et al.* Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes. *Curr Genomics.* **8** (4), 234-251, (2007).
16. Hammerschmidt, S. I. *et al.* Stromal mesenteric lymph node cells are essential for the generation of gut-homing T cells *in vivo*. *J Exp Med.* **205** (11), 2483-2490 (2008).
17. Dominici, M. *et al.* Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy.* **8** (4), 315-317 (2006).
18. Baddoo, M. *et al.* Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. *J Cell Biochem.* **89** (6), 1235-1249 (2003).
19. Furger, K. A., Menon, R. K., Tuck, A. B., Bramwell, V. H., & Chambers, A. F. The functional and clinical roles of osteopontin in cancer and metastasis. *Curr Mol Med.* **1** (5), 621-632 (2001).
20. Radisky, E. S., & Radisky, D. C. Matrix metalloproteinases as breast cancer drivers and therapeutic targets. *Front Biosci (Landmark Ed).* **20** 1144-1163 (2015).
21. Radisky, E. S., & Radisky, D. C. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. *J Mammary Gland Biol Neoplasia.* **15** (2), 201-212 (2010).
22. Radisky, E. S., & Radisky, D. C. Stromal induction of breast cancer: inflammation and invasion. *Rev Endocr Metab Disord.* **8** (3), 279-287 (2007).
23. Kakinuma, T., & Hwang, S. T. Chemokines, chemokine receptors, and cancer metastasis. *J Leukoc Biol.* **79** (4), 639-651 (2006).
24. Zlotnik, A. Chemokines and cancer. *Int J Cancer.* **119** (9), 2026-2029 (2006).
25. Schlesinger, M., & Bendas, G. Vascular cell adhesion molecule-1 (VCAM-1)--an increasing insight into its role in tumorigenicity and metastasis. *Int J Cancer.* **136** (11), 2504-2514 (2015).
26. Cook, K. L., Shajahan, A. N., & Clarke, R. Autophagy and endocrine resistance in breast cancer. *Expert Rev Anticancer Ther.* **11** (8), 1283-1294 (2011).
27. Singh, P., Alex, J. M., & Bast, F. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. *Med Oncol.* **31** (1), 805 (2014).
28. Lee, S. H., Jeong, D., Han, Y. S., & Baek, M. J. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. *Ann Surg Treat Res.* **89** (1), 1-8 (2015).
29. Erdmann, R. B., Gartner, J. G., Leonard, W. J., & Ellison, C. A. Lack of functional TSLP receptors mitigates Th2 polarization and the establishment and growth of 4T1 primary breast tumours but has different effects on tumour quantities in the lung and brain. *Scand J Immunol.* **78** (5), 408-418 (2013).
30. Chambers, A. F. *et al.* Steps in tumor metastasis: new concepts from intravital videomicroscopy. *Cancer Metastasis Rev.* **14** (4), 279-301 (1995).
31. Chiang, A. C., & Massague, J. Molecular basis of metastasis. *N Engl J Med.* **359** (26), 2814-2823 (2008).
32. Gupta, G. P. *et al.* Identifying site-specific metastasis genes and functions. *Cold Spring Harb Symp Quant Biol.* **70** 149-158 (2005).

33. Frantz, C., Stewart, K. M., & Weaver, V. M. The extracellular matrix at a glance. *J Cell Sci.* **123** (Pt 24), 4195-4200 (2010).
34. Price, A. P., England, K. A., Matson, A. M., Blazar, B. R., & Panoskaltsis-Mortari, A. Development of a decellularized lung bioreactor system for bioengineering the lung: the matrix reloaded. *Tissue Eng Part A.* **16** (8), 2581-2591 (2010).
35. Bonnans, C., Chou, J., & Werb, Z. Remodelling the extracellular matrix in development and disease. *Nat Rev Mol Cell Biol.* **15** (12), 786-801 (2014).
36. Hynes, R. O. The extracellular matrix: not just pretty fibrils. *Science.* **326** (5957), 1216-1219 (2009).
37. Psaila, B., & Lyden, D. The metastatic niche: adapting the foreign soil. *Nat Rev Cancer.* **9** (4), 285-293 (2009).
38. Lee, R. H., Oh, J. Y., Choi, H., & Bazhanov, N. Therapeutic factors secreted by mesenchymal stromal cells and tissue repair. *J Cell Biochem.* **112** (11), 3073-3078 (2011).